Treatment of Major Depression

Major depression is a debilitating psychiatric condition in which standard antidepressants, which primarily target serotonin and norepinephrine systems, fail roughly one in three patients—a clinical reality that has pushed researchers toward the brain's glutamate system as an alternative target. Ketamine, an NMDA receptor antagonist originally used as an anesthetic, can lift depressive symptoms within hours rather than weeks, a speed that has reshaped thinking about the neurobiological mechanisms underlying mood disorders and sparked intensive investigation into synaptic plasticity and glutamate signaling. Current research is working to clarify exactly how blocking NMDA receptors produces antidepressant effects, whether those effects can be sustained without the cognitive side effects and abuse potential that ketamine carries, and how to identify which patients with treatment-resistant depression are most likely to respond. These questions are driving the development of more selective glutamate-targeting compounds and refining the clinical criteria used to evaluate when and for whom each intervention is appropriate.

Works

64,731

Total citations

1,406,751

Keywords

DepressionAntidepressantKetamineNMDA ReceptorTreatment-Resistant DepressionNeurobiological Mechanisms